• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Monday, August 31, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News

Long-term use of opioid patches common among persons with Alzheimer’s disease

Bioengineer by Bioengineer
November 14, 2016
in Science News
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Approximately seven per cent of persons with Alzheimer's disease use strong pain medicines, opioids, for non-cancer pain for a period longer than six months, according to a recent study conducted at the University of Eastern Finland. One third of people initiating opioid use became long-term users, and long-term use was heavily associated with transdermal opioid patches. The results were published in PAIN.

The researchers found that long-term use of opioids was approximately as common among persons with Alzheimer's disease as it was among those without it. However, long-term use of transdermal patches was twice as common among persons with Alzheimer's disease, while tablet form opioids were more common among those without Alzheimer's disease. In addition, long-term opioid use together with benzodiazepines was common, which is worrying as both medicines cause drowsiness. The use of opioids was studied from the date of Alzheimer's disease diagnosis until death or admission into a long-term care facility. Those with active cancer treatment were excluded from the analysis.

Long-term opioid use is a problematic practice for non-cancer pain. Evidence of its benefits is limited, and the risk of adverse effects is increased compared to short-term treatment. Further, research on the benefits and adverse effects of long-term opioid use is very scarce among older adults and especially those with dementia. Changing doses and stopping medication when using patch-form opioids requires more time and thus, entails more careful monitoring. Pain, the need for analgesics, and possible adverse effects related to analgesics should be assessed regularly among persons with dementia.

The study is part of the MEDALZ cohort, which included 67,215 persons with Alzheimer's disease diagnosed during 2005-2011, of whom 13,111 initiated opioid use. Each person with the disease was matched with a comparison person without Alzheimer's disease of the same age, gender and region of residence. Data for the study were derived from Finnish nationwide registers.

###

For more information, please contact: Aleksi Hamina, MSc (Pharm), PhD student, School of Pharmacy, University of Eastern Finland, Kuopio, aleksi.hamina(at)uef.fi

Heidi Taipale, post-doctoral researcher, School of Pharmacy, University of Eastern Finland, heidi.taipale(at)uef.fi

Research article: Long-term use of opioids for non-malignant pain among community-dwelling persons with and without Alzheimer's disease in Finland: a nationwide register-based study. Aleksi Hamina, Heidi Taipale, Antti Tanskanen, Anna-Maija Tolppanen, Niina Karttunen, Liisa Pylkkänen, Jari Tiihonen, Sirpa Hartikainen. PAIN, published online 14 November 2016. doi: 10.1097/j.pain.0000000000000752

Media Contact

Aleksi Hamina
[email protected]
@UniEastFinland

http://www.uef.fi

via scienmag.com

Share12Tweet8Share2ShareShareShare2

Related Posts

β-Sitosterol from Ipomoea carnea Jacq. As a promising anti-inflammatory agent: Evidence from in silico modeling and in vitro validation

β-Sitosterol from Ipomoea carnea Jacq. As a promising anti-inflammatory agent: Evidence from in silico modeling and in vitro validation

August 31, 2026
Design, fabrication and characterization of a wearable Fiber Bragg grating sensor for cardiorespiratory monitoring using finger plethysmography

Design, fabrication and characterization of a wearable Fiber Bragg grating sensor for cardiorespiratory monitoring using finger plethysmography

August 31, 2026

KAIST opens the era of industrial-scale microbial foods, proposing growth strategies for the next-generation protein market

August 31, 2026

Virologist awarded $2 million NIH grant to investigate how virus-infected cells live and die

August 31, 2026
Please login to join discussion

POPULAR NEWS

  • β-Sitosterol from Ipomoea carnea Jacq. As a promising anti-inflammatory agent: Evidence from in silico modeling and in vitro validation

    29 shares
    Share 12 Tweet 7
  • Design, fabrication and characterization of a wearable Fiber Bragg grating sensor for cardiorespiratory monitoring using finger plethysmography

    29 shares
    Share 12 Tweet 7
  • KAIST opens the era of industrial-scale microbial foods, proposing growth strategies for the next-generation protein market

    29 shares
    Share 12 Tweet 7
  • Virologist awarded $2 million NIH grant to investigate how virus-infected cells live and die

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

β-Sitosterol from Ipomoea carnea Jacq. As a promising anti-inflammatory agent: Evidence from in silico modeling and in vitro validation

Design, fabrication and characterization of a wearable Fiber Bragg grating sensor for cardiorespiratory monitoring using finger plethysmography

KAIST opens the era of industrial-scale microbial foods, proposing growth strategies for the next-generation protein market

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 85 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.